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Abstract
Nephrotic syndrome is one of the most common glomerular disorders in childhood. Glucocorticoids have been the cornerstone of
the treatment of childhood nephrotic syndrome for several decades, as the majority of children achieves complete remission after
prednisone or prednisolone treatment. Currently, treatment guidelines for the first manifestation and relapse of nephrotic syn-
drome are mostly standardized, while large inter-individual variation is present in the clinical course of disease and side effects of
glucocorticoid treatment. This review describes the mechanisms of glucocorticoid action and clinical pharmacokinetics and
pharmacodynamics of prednisone and prednisolone in nephrotic syndrome patients. However, these mechanisms do not account
for the large inter-individual variability in the response to glucocorticoid treatment. Previous research has shown that genetic
factors can have a major influence on the pharmacokinetic and dynamic profile of the individual patient. Therefore, pharmaco-
genetics may have a promising role in personalized medicine for patients with nephrotic syndrome. Currently, little is known
about the impact of genetic polymorphisms on glucocorticoid response and steroid-related toxicities in children with nephrotic
syndrome. Although the evidence is limited, the data summarized in this study do suggest a role for pharmacogenetics to improve
individualization of glucocorticoid therapy. Therefore, studies in larger cohorts with nephrotic syndrome patients are necessary to
draw final conclusions about the influence of genetic polymorphisms on the glucocorticoid response and steroid-related toxicities
to ultimately implement pharmacogenetics in clinical practice.
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Introduction
Nephrotic syndrome is one of the most common glomerular
disorders in children and affects 1–7 per 100,000 children per
year (Dutch data 1.52/100,000) with a male predominance
(2:1) [1]. The disease is characterized by the triad of severe
proteinuria, hypoalbuminemia, and edema. Glucocorticoids
have been the cornerstone of the treatment of childhood ne-
phrotic syndrome for over 60 years, as over 80–90% of the
patients achieve complete remission with prednisone or pred-
nisolone treatment [2]. Unfortunately, 80% of these patients
will have one or several relapses and will need additional
courses of glucocorticoid therapy. Furthermore, approximate-
ly 10% of children with nephrotic syndrome are steroid resis-
tant and do not respond to the standard steroid treatment reg-
imen. Treatment guidelines for the first manifestation and a
relapse of steroid-sensitive nephrotic syndrome are mostly
standardized and based on practice guidelines rather than clin-
ical trials [3]. As the optimal glucocorticoid dosing regimens
for childhood nephrotic syndrome are still under debate and
large-scale clinical trials are lacking, current clinical practice
among physicians is variable [4], especially in the treatment of
subsequent relapses and the choice of second-line immuno-
suppressive drugs. Unfortunately, the variability in the treat-
ment of nephrotic syndrome is mostly based on the protocol
preference of the physician, rather than the individual
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characteristics of the patient. Therefore, clinical trials are
needed to develop international treatment guidelines with rec-
ommendations for several aspects of the treatment of nephrot-
ic syndrome. Recently, a nationwide study in the Netherlands
showed that duration of corticosteroids for the initial presen-
tation had no impact on subsequent relapses [5]. Furthermore,
a recently published abstract of the PREDNOS study indicat-
ed no clinical benefit associated with an extended steroid
course for the initial presentation in UK children [6].
Currently, a few clinical trials are underway to further inves-
tigate the optimal dosing regimens for both the first manifes-
tation (https://clinicaltrials.gov/ct2/show/NCT02649413?
recrs=abdf&cond=Nephrotic+Syndrome&age=0&draw=
2&rank=13) as well as relapses of nephrotic syndrome [7].
Large inter-individual variation is present in children with
nephrotic syndrome regarding both the clinical course of disease
and the intensity and spectrum of side effects of its treatment.
Nephrotic syndrome is characterized by podocyte foot process
effacement; however, the exact mechanism of disease is still
largely unknown and often debated. Several etiologies have
been investigated over the years, and different subgroups of
the disease are likely to have a different pathogenesis [8, 9].
Damage to the filtration barrier can be caused by genetic defects
primarily affecting podocytes. Patients with an underlying ge-
netic defect are often primary steroid resistant, and to date, 53
genes associated with steroid-resistant nephrotic syndrome have
been identified [10]. Furthermore, a substantial proportion of the
patients is likely to have an immune-mediated circulating factor
disease. These patients are also often steroid resistant, but screen
negative for the known steroid-resistant nephrotic syndrome
genes. The existence of a circulating permeability factor would
explain the rapid recurrence of proteinuria after kidney trans-
plantation in some patients with nephrotic syndrome [11, 12].
Many candidates have been identified over the years; however,
the definitive factor remains to be discovered [13]. Lastly, in-
volvement of the immune system in the pathogenesis of ne-
phrotic syndrome is highly suspected as relapses often occur
after the immune system is triggered by an infection, allergy,
or vaccination, and glucocorticoid treatment is effective in most
patients. Nephrotic syndrome has been considered to be a Tcell
disorder based on several observations, including remission fol-
lowing measles infection, the association with Hodgkin disease,
and the response to immunosuppressive drugs [9]. Furthermore,
in the last few years, a potential role for B cells has been pro-
posed as well due to the effectiveness of B cell depletion with
rituximab in patients with nephrotic syndrome [9, 14].
All in all, most children with nephrotic syndrome
have a minimal change disease [15] and, therefore, the
large inter-patient variability cannot fully be attributed to
the disease histology. Previous research has indicated
that pharmacogenetics can have an influence on both
pharmacokinetics (PK) and pharmacodynamics (PD) of
the individual patient [16]. Genetic factors influencing
the individual pharmacokinetic and pharmacodynamic
profile may account for 20–95% of the variability in
the efficacy and side effects of medication [17]. Each
of the processes involved in PK and PD can potentially
be influenced by a clinical significant genetic variation
[18]. Therefore, pharmacogenetics may have a promising
role in personalized medicine. By implementing pharma-
cogenetics in the clinical work-up of the patients, this
may ultimately lead to individualized drug therapy to
maximize drug efficacy and minimize drug toxicity. In
the era of precision medicine, however, current knowl-
edge on the influence of pharmacogenetics on the steroid
response in nephrotic syndrome is limited [19].
This review describes the mechanisms of glucocorticoid
action and clinical PK and PD of prednisone and predniso-
lone in nephrotic syndrome patients. Furthermore, the cur-
rent data available on pharmacogenetics of prednisone and
prednisolone in patients with nephrotic syndrome is sum-
marized and areas for future research to improve individu-
alization of glucocorticoid therapy in children with nephrot-
ic syndrome are identified.
Mechanisms of glucocorticoid action
Glucocorticoids are potent anti-inflammatory and im-
munosuppressant drugs. The effects of glucocorticoids
are mediated by both genomic and non-genomic mech-
anisms. Genomic mechanisms implicate the activation
or repression of specific genes encoding anti- and
pro-inflammatory proteins. As a consequence of the
time-consuming mRNA transcription and translation,
the genomic glucocorticoid action is characterized by
a slow onset of the response. In contrast, non-genomic
mechanisms do not influence gene expression and have
a rapid onset and a short duration of the effect [20].
Genomic mechanisms (Fig. 1)
Glucocorticoids are, like other steroid hormones, lipophilic
molecules that can easily diffuse across the cell membrane
and bind to the glucocorticoid receptors (GRs) in the cyto-
plasm [21]. The inactive GR is bound to a chaperone protein
complex to keep the inactive GR in the correct folding for
hormone binding and prevent nuclear localization of unoccu-
pied GRs [19, 22, 23]. When glucocorticoids enter the cell
after passive diffusion and bind to the GR in the cytoplasm,
a glucocorticoid receptor/glucocorticoid (GR/GC) complex is
formed. Subsequently, the chaperone protein complex disso-
ciates, allowing the transfer of the GR/GC complex into the
nucleus. The mechanism of nuclear translocation involves the
nuclear import proteins importin-α and importin-13 (IPO13)
[24]. After entering the nucleus, the activated GR/GC
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complex binds to the DNA or interacts with co-activator com-
plexes. The activated GR/GC complex exerts its
anti-inflammatory and immunosuppressive effects by increased
expression of anti-inflammatory genes (transactivation) and de-
creased expression of pro-inflammatory genes (transrepression)
[23, 25]. Furthermore, the GR/GC complex can, either directly
or indirectly, interact with pro-inflammatory transcription fac-
tors nuclear factor κB (NF-κB) and activator protein 1 (AP-1)
and thus reduce their activity [20, 26].
Non-genomic effects
The non-genomic mechanisms of glucocorticoid action re-
main largely undefined. Glucocorticoids affect the physi-
cochemical property of cell membranes, directly or
through binding to intracellular or membrane-bound GRs
[27]. The effects result in the inhibition of inflammatory
cell function [28]. Another hypothesis is that non-genomic
effects are mediated after GR/GC binding. When glucocor-
ticoids bind to the GR, the aforementioned chaperone pro-
teins are released. The release of signaling molecules from
the multiprotein complex is also considered to be respon-
sible for rapid glucocorticoid effects [29].
Pharmacokinetics
Pharmacokinetics describes the study of what the body does to
a drug. PK involves the processes of absorption, distribution,
metabolism, and excretion, often abbreviated as ADME.
Prednisone and prednisolone
For the treatment of nephrotic syndrome, both prednisone and
prednisolone are frequently used glucocorticoids. Prednisone is
a prodrug of prednisolone and is bioactivated by the enzyme
11β-hydroxysteroid dehydrogenase (11β-HSD)-1. The conver-
sion of prednisone into prednisolone occurs rapidly, and plasma
concentrations of both substances reach their peaks at approx-
imately 0.5–3 h after prednisone administration, in both patients
with and without nephrotic syndrome [20, 30–33]. In addition,
inter-conversion is present between both substances and this
varies with time and dose. However, prednisolone concentra-
tions are four- to tenfold higher than prednisone concentrations.
In children with nephrotic syndrome, both in the active phase
and in remission, similar ratios were found, which indicates that
nephrotic syndrome does not influence the conversion from
prednisone into prednisolone [30–32, 34].
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Fig. 1 Molecular mechanisms of
glucocorticoid action. AP-1,
activator protein 1; IκB, inhibitor
of kappa B; IPO-13, importin-13;
NF-κB, nuclear factor κB; GRE,
glucocorticoid response elements
Absorption
Both prednisone and prednisolone are well absorbed after oral
administration. A variable systemic bioavailability for predni-
sone and prednisolone has been reported in the literature: 84 ±
13 and 99 ± 8%, respectively [20]. The high variability in
b ioava i l ab i l i ty i s mos t l ike ly main ly based on
inter-individual differences rather than the choice of predni-
sone or prednisolone [35]. In the Kidney Disease: Improving
Global Outcomes (KDIGO) guideline for glomerulonephritis,
prednisone and prednisolone are considered equivalent and
identical dosages are used for the standardized treatment reg-
imens for patients with nephrotic syndrome [3]. Peak plasma
concentrations are reached at approximately 0.5–3 h after ad-
ministration. Food intake is generally considered to prolong
the time to maximum drug concentration (Tmax), but not the
extent of drug absorption [36].
Nephrotic syndrome
In patients with nephrotic syndrome, a similar bioavailability
profile has been described, indicating that the nephrotic state
does not influence the absorption of prednisolone and predni-
sone [34, 37] (Fig. 2).
Distribution
The volume of distribution of prednisolone and prednisone in
adults is 0.64 l/kg [38] and 0.4–1.0 l/kg [39], respectively. The
total plasma PK of prednisolone and prednisone appears non-
linear, due to non-linear protein binding. The protein-free PK,
however, is linear. Non-linear protein binding is most evident in
the dose range between 5 and 50 mg [32]. Prednisolone binds to
the glycoprotein transcortin (i.e., corticosteroid-binding globulin)
and to albumin. Transcortin is a small (50–60 kDa), high-affinity,
low-capacity protein with normal blood concentrations of 32.0–
50.0 mg/l. In contrast, albumin (60 kDa) has a low affinity but
high capacity [32, 40]. Protein binding of prednisolone decreases
non-linearly from approximately 95% at plasma concentrations
of 200 μg/l down to 60–70% at plasma concentrations of
800μg/l. Subsequently, a dose-dependent increase in the volume
of distribution and drug clearance is observed [20].
Nephrotic syndrome
Patients with nephrotic syndrome have decreased serum albu-
min and transcortin levels in the active phase of disease, lead-
ing to a decreased protein binding of prednisone and prednis-
olone [37, 38]. When the unbound fraction increases due to
less protein binding, the drug is eliminated more rapidly and
the volume of distribution of total prednisolone increases as
the displaced drug spreads out. The end result is an initial
increase in unbound concentration, a decrease in total drug
concentration, and no change in the steady-state unbound con-
centration (Fig. 3). These findings underline the necessity of
evaluating unbound concentrations in pharmacological re-
search. Recently, Teeninga et al. showed a good correlation
between salivary prednisolone levels and free serum prednis-
olone levels in healthy volunteers and pediatric nephrotic syn-
drome patients, indicating the potential use of saliva as a
non-invasive and feasible method for drug monitoring of
prednisolone [41].
Several pharmacokinetic studies performed in both pediat-
ric [30, 31, 34, 40] and adult [37, 38, 42] nephrotic syndrome
patients have confirmed the increase in unbound fraction, but
unchanged steady-state unbound concentration of predniso-
lone. Moreover, pharmacokinetic studies performed in chil-
dren with nephrotic syndrome both in the active phase of
disease and in remission showed that free prednisolone con-
centrations during the active phase did not significantly differ
from those observed during remission [31]. Furthermore,
pharmacokinetic studies for other highly protein-bound drugs
showed similar results with an increase of total volume of
distribution, total clearance, and free fraction of the drugs,
but unchanged free drug concentrations in steady state [43].
Metabolism
Intracellular metabolism by 11β-HSD controls the availability
of prednisolone for binding to the glucocorticoid and miner-
alocorticoid receptors. Two types of 11β-HSD are present in
the body. 11β-HSD-1 acts primarily as a reductase and con-
verts the inactive prednisone into the active prednisolone.
11β-HSD-2 acts primarily as an oxidase and converts pred-
nisolone to prednisone, thereby protecting the mineralocorti-
coid receptor from occupation by cortisol and prednisolone
[44]. The undesired mineralocorticoid effects of glucocorti-
coid treatment will most likely be pronounced when the ca-
pacity of 11β-HSD-2 is exceeded. Therefore, the mineralo-
corticoid effects of glucocorticoids might depend on the ad-
ministration scheme. A low glucocorticoid dose leading to
concentrations just above the protective capacity of
11β-HSD-2 is expected to have reduced mineralocorticoid
effects when administered as two dose fractions, because both
concentration peaks would not exceed 11β-HSD-2 capacity.
In contrast, higher glucocorticoid doses, exceeding the
11β-HSD-2 capacity and even leading to saturation of the
mineralocorticoid receptor, are expected to have enhanced
mineralocorticoid effects when administered as two dose frac-
tions, because the total time during which mineralocorticoid
receptors are occupied would be prolonged.
Prednisolone and prednisone are primarily cleared from the
body by hepatic metabolism involving phase I and phase II
reactions. The most important enzyme system of phase I me-
tabolism is cytochrome P450. However, for the prednisone/
prednisolone metabolism, the degree of involvement of
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specific cytochrome P450 (CYP)3A isoenzymes has not been
fully elucidated yet. Nevertheless, co-administration of the
strong CYP3A4 inhibitor ketoconazole is shown to increase
total and unbound prednisolone concentrations in plasma by
about 50% due to a decreased clearance [45]. In line with this,
previous research has shown co-administration of enzyme in-
ducers to cause an increased clearance and decreased half-life
of prednisolone [46–48].
Furthermore, in vitro data suggest that prednisolone is also
a substrate of P-glycoprotein. P-glycoprotein is an
ATP-dependent efflux membrane transporter, which is widely
distributed throughout the body and highly expressed in the
small intestine and kidneys. Expression of P-glycoprotein in
the intestinal epithelium limits the absorption of drug sub-
strates from the gastrointestinal tract. Therefore, theoretically,
co-administration of P-glycoprotein inhibitors could increase
glucocorticoid absorption and oral bioavailability and might
affect glucocorticoid distribution [20]. A previous study con-
ducted in adult renal patients, however, showed a normal me-
tabolism of prednisolone in patients treated with cyclosporine,
which is a P-glycoprotein inhibitor [49].
Nephrotic syndrome
For patients with nephrotic syndrome, different dosing regi-
mens have been investigated. Single daily dosing appears to
be as effective as multiple daily dosing in maintaining remis-
sion in children [50]. Serious side effects, including hyperten-
sion, Cushingoid appearance, and obesity, were less common
in patients receiving the single daily dose compared to patients
receiving divided doses [50]. We hypothesize that this might
be due to continuously exceeding the 11β-HSD-2 capacity in
case of multiple daily dosing as a consequence of the high
doses of steroids given in patients with nephrotic syndrome.
Whether P-glycoprotein inhibitors are able to increase glu-
cocorticoid availability in patients with nephrotic syndrome is
unknown. In addition, glucocorticoids are known to affect the
PK of other drugs by enzyme induction as well by inducing
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Fig. 3 Unchanged unbound (free) concentration in patients with nephrotic syndrome
Fig. 2 ADME prednisone/prednisolone in patients with nephrotic
syndrome
CYP3A4 [51] and P-glycoprotein [52]; however, the clinical
importance of enzyme induction by prednisone/prednisolone
is largely unknown [20].
Excretion
P-glycoprotein is also located in the liver and kidney, resulting
in enhanced excretion of drug substrates into bile and urine,
respectively. In this case, co-administration of P-glycoprotein
inhibitors could potentially result in decreased excretion of
prednisone/prednisolone and an increased retention time
[53]. The previously mentioned pharmacokinetic study in re-
nal transplant patients, however, also showed a normal meta-
bolic and renal clearance of prednisolone in the presence of
cyclosporine [49]. Elimination half-lives (T1/2) in adults are
3.3 ± 1.3 h for prednisone and 3.2 ± 1.0 h for prednisolone
[20]. In a pharmacokinetic study performed in children, lower
mean elimination half-lives of 2.2 ± 0.5 h were found [33].
Nephrotic syndrome
In the aforementioned study, children with a variety of dis-
eases (e.g., nephrotic syndrome, asthma, systemic lupus ery-
thematosus, congenital virilizing adrenal hyperplasia) were
included. Children with congenital virilizing adrenal hyper-
plasia were considered to be comparable to normal subjects.
No difference regarding elimination half-lives was found be-
tween this group and the children with nephrotic syndrome
[33]. Similarly, Rocci et al. found no significant difference in
half-life between pediatric nephrotic syndrome patients in re-
mission and asthmatic controls. However, in the active phase
of disease, the nephrotic syndrome patients did show in-
creased T1/2 values, which may be explained by the larger
volume of distribution in active disease [34]. In patients with
nephrotic syndrome, total prednisolone clearance increases
proportionally to the increased unbound fraction of predniso-
lone [34, 38, 42] (Fig. 3). Renal excretion of unchanged drugs
is approximately 2–5% for prednisone and 11–24% for pred-
nisolone after administration of either one of the drugs [32].
Summary
In patients with nephrotic syndrome, the unbound fraction of
prednisolone increases due to saturable protein binding.
Subsequently, this leads to more rapid elimination and an in-
crease in apparent volume of distribution, in the end, leading
to a decrease in total drug concentrations and no change in the
steady-state unbound (pharmacologically active) concentra-
tion (Fig. 3). Therefore, dose adjustment of prednisone/
prednisolone is not necessary in nephrotic syndrome patients
with normal renal clearance.
Pharmacodynamics
Pharmacodynamics refers to what the drug does to the body,
including the time course and intensity of therapeutic and
adverse effects.
Therapeutic effects
Clinical efficacy depends on both pharmacokinetic (e.g., what
the body does to a drug) and pharmacodynamic (e.g., what the
drug does to the body) characteristics of a drug. In case of
glucocorticoids, PD may vary greatly among different gluco-
corticoids, diseases, and individuals. These differences may be
explained by a variety of factors: different numbers of GRs per
cell, a different glucocorticoid binding affinity, GR diversity,
regulatory factors that control gene translation and protein pro-
duction, and possibly also, differences in non-genomic mecha-
nisms between cell types [54]. One way of comparing drug
potency is by the concentration at which 50% of the maximum
effect (EC50) is achieved. Furthermore, potency is also depen-
dent on the effect monitored. Potential biomarkers for gluco-
corticoids are endogenous cortisol, T helper and T suppressor
lymphocytes, and neutrophil count [55].
Adverse effects
Prednisolone and prednisone therapy have been associated
with a broad range of toxicities. Adverse effects are more
common in patients receiving glucocorticoids in high doses
or over a long period of time. Potential adverse effects include
skin fragility, bodyweight gain, increased risk of infections,
and fractures. Important cardiovascular and metabolic effects
are hypertension, hyperglycemia, and dyslipidemia [48].
Whereas most anti-inflammatory effects of glucocorticoids
are consequences of transrepression of pro-inflammatory and
immune genes, adverse events appear to largely result from
transactivation that leads to increased expression of regulatory
and anti-inflammatory proteins [25, 27, 56].
Nephrotic syndrome
As it stands, it is not completely understood how prednisolone
achieves remission of nephrotic syndrome. High variability
exists between individuals with nephrotic syndrome regarding
both the efficacy and side effects of prednisone/prednisolone
[57]. Furthermore, the molecular basis for the development of
clinical resistance to glucocorticoid therapy is unclear in pa-
tients with nephrotic syndrome. Inter-individual differences in
glucocorticoid handling and metabolism may partly explain
the variability in the response to prednisone/prednisolone
treatment. However, as previously described in the introduc-
tion, differences in disease histology, podocytes, and immu-
nological characteristics of the individual patient may also
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play a significant role. Different hypotheses exist to explain
the mechanism of action of prednisone/prednisolone in pa-
tients with nephrotic syndrome. These hypotheses go beyond
the conventional anti-inflammatory or immunosuppressive
actions, as it is unlikely that the effect is completely due to
conventional anti-inflammatory effects of these drugs, since
glomerular inflammation is mostly absent in steroid-sensitive
nephrotic syndrome.
Previous research has indicated that glomerular podocytes
may be a direct target of glucocorticoids in patients with nephrot-
ic syndrome as human podocytes express GRs [58]. The benefi-
cial effect of glucocorticoids might be due to direct protection of
podocytes from injury and/or promotion of podocyte repair. Xing
et al. showed that dexamethasone upregulated the expression of
nephrin [59]. Nephrin is a key component of the slit diaphragm,
the main site of control of glomerular permeability. This has
resulted in the hypothesis that glucocorticoids act directly on
podocytes via promotion of repair with enhanced process forma-
tion and upregulation of nephrin. Furthermore, podocyte foot
processes consist of cortical actin filaments and actin-associated
proteins, which ensure the dynamic maintenance and reorgani-
zation of the cytoskeleton. In vitro studies have shown the direct
effects of glucocorticoids on podocytes by protection of cultured
podocytes via actin filament stabilization and prevention of apo-
ptosis [60, 61]. The effect on apoptosis [61] and upregulation of
nephrin [59] appeared to be dose-dependent, which might be an
explanation for the observed differences in clinical response to
glucocorticoids. Another in vitro study, performed by Guess
et al., demonstrated functional glucocorticoid signaling by mul-
tiple glucocorticoid-induced responses, including downregula-
tion of the GR [62].
Gamal et al. reported that glomerular GR expression was
significantly higher inminimal change early responders in com-
parison to late responders. Furthermore, a significantly lower
glomerular GR expression was found in patients with a
steroid-resistant nephrotic syndrome compared to early re-
sponders and late responders. Therefore, evaluation of glomer-
ular GR expression at the time of diagnosis can aid in prediction
of the response to steroid therapy. This way, exposure to inef-
fective treatment courses may be prevented in children with
nephrotic syndrome [63]. Unfortunately, this technique requires
a kidney biopsy and, in daily clinical practice, a kidney biopsy
is generally not performed at the time of diagnosis in children
with nephrotic syndrome. Therefore, additional approaches are
needed to predict the response to steroid therapy, of which
pharmacogenetics may be a promising option.
Pharmacogenetics
It is well known that different patients respond in different
ways to the same medication. Many non-genetic factors influ-
ence the individual differences in drug response, including
age, sex, disease, organ function, concomitant therapy, drug
adherence, and drug interactions (for a review on such factors,
see [20, 48]). In addition, genetic factors may also have a
major influence on the efficacy of a drug and risk of side
effects [18, 64]. Pharmacogenetics is the study of the role of
inheritance in inter-individual variation in drug response.
Genetic factors influencing the patient pharmacokinetic or
pharmacodynamic profiles may account for 20–95% of vari-
ability in the efficacy and side effects of therapeutic agents
[17]. For example, polymorphisms in the CYP3A5 gene ac-
count for 40–50% of the variability in tacrolimus dose require-
ment in Caucasians [65]. After administration, the drug is
absorbed and distributed to the site of action. It interacts with
targets (such as receptors and enzymes), undergoes metabo-
lism, and is then excreted. Each of these processes could po-
tentially involve a clinical significant genetic variation [18].
Understanding the basis of such variations, i.e., pharmacoge-
netics, is vital to come to personalized medicine, which ulti-
mately may lead to individualized drug therapy to maximize
drug efficacy and minimize drug toxicity.
Clinical practice
In children with nephrotic syndrome, large inter-individual var-
iability is present in the course of disease, and efficacy and side
effects of glucocorticoids. As the variable response to glucocor-
ticoids in patients with nephrotic syndrome cannot completely
be attributed to the disease histology, it is difficult to predict the
response based on clinical observations alone. For nephrotic
syndrome, research on the impact of genetic polymorphisms
on steroid response and susceptibility to steroid-related toxic-
ities is limited [19]. For a few other diseases, however, pharma-
cogenetics has already been implemented in clinical practice
[66, 67]. Furthermore, in the field of pediatric nephrology,
new guidelines on tacrolimus dosing recommend involvement
of CYP3A5 genotyping to optimize the immunosuppressive
treatment of the individual transplant patients [68].
In line with the aforementioned examples, we believe
that the involvement of pharmacogenetics in the work-up
of nephrotic syndrome patients as well might be benefi-
cial, preventing exposure to ineffective drug courses and
minimizing drug toxicity. As the mechanism of action of
glucocorticoids involves numerous receptors, enzymes,
and proteins, a variety of potential targets of genetic poly-
morphisms may be present. Although limited evidence is
available, an overview of previously conducted studies on
pharmacogenetics of prednisone and prednisolone in pa-
tients with nephrotic syndrome is provided below. Table 1
(glucocorticoid targets) and Table 2 (glucocorticoid PK)
provide an overview and brief description of the most
important studies conducted in pediatric patients with ne-
phrotic syndrome in which a positive association between
the polymorphism and steroid response was described. A
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summary of the mechanisms and most important results is
provided for the targets involved.
Targets
Glucocorticoid receptor
Polymorphisms in the GR gene (NR3C1) are known to be
associated with variations in the GR function, because they
may alter the formation of the GR/GC complex. Therefore, the
hypothesis is that genetic alterations in the gene encoding for
the GR receptor may account for some degree of
inter-individual variability in the glucocorticoid response and
steroid-related toxicity in individuals [88]. Three polymor-
phisms are known to be associated with reduced sensitivity
in both endogenous and exogenous glucocorticoids: TthIIII
(rs10052957), ER22/23K (rs6189/rs6190), and GR-9β
(rs6198). In contrast, the polymorphisms N363S (rs6195)
and BC1I (rs41423247) are associated with an increased sen-
sitivity to glucocorticoids [88, 89]. Increased glucocorticoid
sensitivity due to a genetic polymorphism might also be asso-
ciated with increased susceptibility to steroid-related toxic-
ities. Previously, Eipel et al. showed that pediatric patients
with acute lymphoblastic leukemia (ALL) carrying the
N363S polymorphism were more prone to steroid-related tox-
icities [90, 91]. In contrast, children with the ER22/23EK
polymorphism were less susceptible [90]. To our knowledge,
the role of genetic polymorphisms in the GR gene in suscep-
tibility of steroid-related toxicities has only been investigated
in patients with nephrotic syndrome in one study. Teeninga
et al. found no association between the GR-9β polymorphism
and side effects [69]. To date, a few studies investigated the
role of NR3C1 polymorphisms on the glucocorticoid response
in pediatric patients with nephrotic syndrome [69–72, 92, 93].
Four studies found a potential influence of genetic polymor-
phisms in the GR gene on the steroid response in patients with
nephrotic syndrome (Table 1).
Glucocorticoid receptor heterocomplex
Components of the glucocorticoid heterocomplex are essential
to keep the GR in the correct folding for hormone binding and
prevent nuclear localization of unoccupied GRs. Abnormalities
in the chaperones and co-chaperones that make up the
heterocomplex may contribute to decreased glucocorticoid re-
sponsiveness, as the integrity of the GR heterocomplex is re-
quired for optimal ligand binding and subsequent activation of
the transcriptional response. For several diseases, which are
treated with glucocorticoids, including nephrotic syndrome, al-
tered levels of chaperone protein hsp90 were found in periph-
eral blood mononuclear cells from individuals with a
steroid-resistant course of disease [94–96]. Although limited,
some evidence exists about the association of polymorphisms
in the gene encoding for one of the co-chaperones, FKBP5,
with steroid resistance in Crohn’s disease [97]. Interestingly,
this could also hold true for nephrotic syndrome patients as
well. Recently, one study was published on the potential role
of FKBP5 polymorphism (rs4713916) in a small group of pe-
diatric nephrotic syndrome patients showing a higher frequency
in patients with a steroid-dependent nephrotic syndrome [73].
Nuclear translocation receptors
Nuclear translocation receptors, known as importins, play
a significant role in the mechanism of glucocorticoid ac-
tion. These receptors are responsible for the effective trans-
port of the GR/GC complex to the cell nucleus. IPO13 is a
primary regulator to facilitate the transfer of the GR/GC
complex across the nuclear membrane. In children with
asthma, polymorphisms encoding the IPO13 gene resulted
in increased sensitivity for glucocorticoids, which was
most likely due to the increased availability of glucocorti-
coids in the nucleus [98]. The role of genetic polymor-
phisms in the gene encoding for IPO13 in patients with
nephrotic syndrome is unknown [19].
Pro- and anti-inflammatory factors
To date, the exact underlying pathophysiological mechanisms
of nephrotic syndrome are still unknown. One of the hypoth-
eses is that nephrotic syndrome is associated with an immu-
noregulatory imbalance between T helper subtype 1 (Th1) and
T helper subtype 2 (Th2) cells. Cytokines produced by the T
helper cells play a role as mediators of inflammation. Several
studies have been conducted in patients with various diseases
to evaluate the association with genetic polymorphisms in the
IL-1, IL-4, IL-6, IL-13, and TNF-α genes. The evidence for
genetic polymorphisms in the cytokine genes in patients with
nephrotic syndrome is, however, limited.
Minimal change nephrotic syndrome is associated with at-
opy and IgE production [99]. T helper subtype 2 cytokines,
such as IL-4 and IL-13, are known to be involved in the
development of atopy. Previously genetic variations of IL-4
and IL-13 and their receptors have been shown to be associ-
ated with predisposition to atopy and/or elevated serum IgE
levels [100]. Several studies have been conducted to investi-
gate the role of polymorphisms in the genes coding for IL-4,
IL-6, and IL-13 in pediatric patients with nephrotic syndrome
[74–76, 101–103]. The IL-4 polymorphism rs2243250 was
associated with nephrotic syndrome and an increased risk of
steroid resistance [74–76]. Furthermore, previous research
conducted by Jafar et al. and Tripathi et al. indicate that a
genetic polymorphism in the IL-6 gene is associated with
decreased responsiveness to steroids [75, 76]. No significant
assoc ia t ion was found between the IL-13 gene
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polymorphisms and disease susceptibility or steroid respon-
siveness [71, 101, 103].
An important pro-inflammatory cytokine is macro-
phage migration inhibitory factor (MIF). MIF has the
unique ability to override the inhibitory effects of gluco-
corticoids on the immune system. Due to its regulatory
properties, MIF is considered a critical mediator in vari-
ous immune and inflammatory diseases. The allele
MIF-173*C (rs755622) is associated with higher serum
MIF levels. Several studies have been conducted to inves-
tigate the potential role of this genetic polymorphism in
the gene encoding for MIF in patients with nephrotic syn-
drome [71, 79–81, 104, 105]. A meta-analysis conducted
by Tong et al. showed that the gene polymorphism
rs755622 plays an important role in the risk of glucocor-
ticoid resistance in patients with nephrotic syndrome
Table 1 Effects of gene polymorphisms affecting glucocorticoid targets in nephrotic syndrome patients
Target Gene (Proposed) mechanism Population
nephrotic
syndrome
Polymorphism
Clinical relevance
Ref.
GR NR3C1 Alteration of GR/GC complex
formation
N = 108
Age 4.0
(3.1–6.5)
GR-9β +
TthIII-1
rs6198 +
rs10052957
Higher incidence of glucocorticoid
dependence
[69]
N = 118
Age 5.1 (± 3.2)
GTA
haplotype
rs33388
rs33389
Bcl-1
Higher glucocorticoid sensitivity [70]
N = 100
Children
rs41423247 Higher incidence of frequent
relapsing nephrotic syndrome
[71]
N = 154
Unknown
rs6196
rs10052957
rs258751
Decreased risk of glucocorticoid
resistance
[72]
GR heterocomplex FKBP5 Alteration of GR activity N = 66
Children
rs4713916 Higher incidence of glucocorticoid
dependence
[73]
Anti-inflammatory
factors
IL-4
promoter
IL-4 production is upregulated in
patients with nephrotic syndrome
N = 58
Children
rs2243250 Higher frequency in patients with
nephrotic syndrome
[74]
N = 150
Age 11.0
(± 6.6)
rs2243250 Association with glucocorticoid
resistance
[75]
N = 150
Children
rs2243250 Association with glucocorticoid
resistance
[76]
IL-4Rα N = 85
Children
rs1805010 Lower frequency in patients with
frequent relapsing nephrotic
syndrome
[77]
IL-6 IL-6 production is increased in
patients with steroid-resistant
nephrotic syndrome
N = 150
Age 11.0
(± 6.6)
rs1800795 Association with glucocorticoid
resistance
[75]
N = 150
Children
rs1800795 Association with glucocorticoid
resistance
[76]
Pro-inflammatory
factors IL-12B-
pro1
Decrease in IL-12 production N = 79
Age 10.7
(± 4.5)
rs17860508 Association with glucocorticoid
dependence
[78]
TNF-α Increased TNF transcription, leading
to an increase in TNF-α synthesis
N = 150
Age 11.0
(± 6.6)
rs1800629 Association with glucocorticoid
resistance
[75]
N = 150
Children
rs1800629 Association with glucocorticoid
resistance
[76]
MIF Increase of MIF level in serum
causes a pro-inflammatory
response
N = 214
Age 3.5 (± 2.9)
rs755622 Association with glucocorticoid
resistance
[79]
N = 257
Age 5.8 (± 4.2)
rs755622 Association with glucocorticoid
resistance
[80]
N = 80
Children
rs755622 Association with glucocorticoid
resistance
[81]
IL interleukin; FKBP5 FK506 binding protein;MIF macrophage migration inhibitory factor; NR3C1 nuclear receptor subfamily 3 group C, member 1;
TNF-α tumor necrosis factor alpha
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[106]. The hypothesis is that the G/C substitution at
173 bp of the MIF gene increases the MIF level in serum
and could therefore cause a pro-inflammatory response,
induce injury to podocytes, and accelerate the progression
of glomerulosclerosis [107]. TNF-α is also an important
pro-inflammatory cytokine involved in the inflammatory
process. Elevation of TNF-α has been found in the plas-
ma and urine of patients with nephrotic syndrome [108,
109]. Conflicting results have been published for the role
polymorphisms in the gene encoding for TNF-α in pa-
tients with nephrotic syndrome [75, 76, 110, 111].
Lastly, Müller-Berghaus et al. investigated the role of
polymorphisms in gene encoding for pro-inflammatory
mediator IL-12B and found an association of the
IL12Bpro-1.1 genotype with a steroid-dependent course
of disease [78].
GLCCI1 (glucocorticoid-induced transcript 1 gene)
Little is known about the exact function of GLCCI1. GLCCI1
was initially described as a thymocyte-specific transcript that
is rapidly upregulated in response to dexamethasone treatment
[112]. In addition, GLCCI1 is expressed in the kidney and, in
particular, in the glomeruli. Knockdown of the GLCCI1 gene
resulted in disruption of the glomerular permeability filter and
podocyte foot process effacement. A genome-wide associa-
tion study in patients with asthma showed a significant asso-
ciation between the genetic polymorphism rs37972 of the
GLCCI1 gene and a decreased response to glucocorticoid in-
halation therapy [113]. In contrast, two studies in pediatric
nephrotic syndrome patients could not confirm the association
between this specific polymorphism and steroid responsive-
ness in patients with nephrotic syndrome [71, 114].
Table 2 Effects of gene
polymorphisms affecting
glucocorticoid pharmacokinetics
in nephrotic syndrome patients
Target Gene (Proposed)
mechanism
Population
nephrotic
syndrome
Polymorphism
Clinical
relevance Ref.
P-glycopro-
tein
MD-
R-1
Enhanced
P-glycoprotein
function
N = 108
Age 11.13
(± 4.83)
rs1128503
rs2032582
rs1045642
Association
with late
response to
glucocorti-
coids
[82]
N = 74
Children
rs1128503 Association
with
glucocorti-
coid
resistance
[83]
N = 138
Age 4.2
(± 1.6)
rs2032582 Association
with
glucocorti-
coid
resistance
[84]
N = 216
Children
rs2032582 Association
with
glucocorti-
coid
resistance
[85]
N = 120
Children
rs1128503 Association
with
glucocorti-
coid
resistance
[86]
N = 100
Children
rs2032582
rs1128503
rs1045642
Association
with
different
medication
regimes
[71]
PXR NR1I2 Decreased
expression of
PXR, leading to
underexpression
of GRs
N = 66
Age 4.9
(± 3.7)
rs3842689 Association
with
glucocorti-
coid
resistance
[87]
MDR-1 multidrug resistance protein 1, PXR pregnane X receptor
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P-glycoprotein
P-glycoprotein is an efflux pump encoded by the multidrug
resistance protein 1 gene (MDR1). Glucocorticoids are known
substrates for P-glycoprotein and may also induce
P-glycoprotein expression [52, 115]. In the kidney,
P-glycoprotein is expressed in the brush border membrane of
proximal tubular epithelial cells. Increased expression of
P-glycoprotein results in decreased intracellular drug concen-
trations and may consequently decrease treatment response.
Previous research has shown higher expression of MDR1 and
increased P-glycoprotein activity in children with
steroid-resistant nephrotic syndrome [116, 117]. To date, ap-
proximately 50 genetic polymorphisms have been reported in
the MDR1 gene. Among the genetic polymorphisms, C1236T
(rs1128503), G2677T/A (rs2032582), and C3435T
(rs1045642) are the most common variants in the coding region
of MDR1. The interpretation of the influence of the genetic
polymorphisms on P-glycoprotein expression, however, is un-
resolved and may vary depending on tissue type, pathological
status, and ethnicity [118]. A recent systematic review on phar-
macogenetics and adverse drug reactions in pediatric oncology
patients indicated protective effects from two genetic polymor-
phisms of the MDR1 gene in methotrexate- and
vincristine-related neurotoxicity in pediatric ALL patients
[119]. In nephrotic syndrome patients, however, no studies have
been conducted to investigate the potential role of genetic poly-
morphisms in the MDR1 gene in steroid-related toxicities.
Several studies have been conducted to evaluate the association
of P-glycoprotein polymorphisms with the responsiveness to
glucocorticoids in patients with nephrotic syndrome. The re-
sults of these studies on the significance of the genetic poly-
morphisms are contradictory [71, 82–84, 86, 104, 120, 121]. A
recent meta-analysis concluded that there is evidence of an
association between rs1128503 and increased risk of steroid
resistance in children with nephrotic syndrome [122].
Pregnane X receptor
Pregnane X receptor (PXR) gene (NR1I2) encodes an intracel-
lular receptor that, upon binding with glucocorticoids or xeno-
biotic substances, activates a set of genes involved in the me-
tabolism of drugs. Turolo et al. described an association of the
presence of a PXR deletion polymorphism (rs3842689) with
steroid resistance. The hypothesis is that a reduced expression
of PXR leads to an underexpression of GRs, which may be the
explanation for the development of steroid resistance [87].
Summary
The results of the aforementioned reported papers are gener-
ally inconclusive and contradictory. However, some genetic
polymorphisms appear to be promising in the prediction of
steroid response or steroid-related toxicities in children with
nephrotic syndrome. Especially, polymorphisms in the genes
encoding for the GR and GR heterocomplex seem to have an
association with steroid responsiveness. Nevertheless, most
studies are hampered by small patient cohorts. Therefore,
studies in larger cohorts with nephrotic syndrome patients
are necessary to draw conclusions about the influence of ge-
netic polymorphisms on the glucocorticoid response.
Furthermore, as mentioned above, pharmacogenetics may al-
so play a role in the intensity and spectrum of side effects.
Currently, little is known about the influence of pharmacoge-
netics on steroid-related toxicities in patients with nephrotic
syndrome. However, as previous research in mostly cancer
patients has shown a potential role of genetic polymorphisms
in the susceptibility on steroid-related toxicities, this area is an
important opportunity for future research as well.
Conclusion
Glucocorticoids are essential in the treatment of childhood ne-
phrotic syndrome. Currently, standardized treatment guidelines
with high doses of prednisone or prednisolone are proposed
worldwide. As current treatment guidelines are largely based
on empiric recommendations rather than clinical trials, large
variability in the treatment of nephrotic syndrome is present
among physicians [4], especially regarding the treatment of
subsequent relapses and the choice of second-line immunosup-
pressive drugs. As large-scale clinical trials are lacking, treat-
ment decisions are frequently based on either the preference or
common practice of the treating physician or guidelines of the
country, rather than the individual characteristics of the patient.
Therefore, effort should be made to first provide international
guidelines based on clinical trials to uniformly treat patients
with nephrotic syndrome. Subsequently, effort should be made
to identify specific markers to individualize treatment, as large
inter-individual differences are present in both the clinical
course of disease and adverse effects of glucocorticoids in chil-
dren with nephrotic syndrome. Pharmacogenetics has a prom-
ising role in working towards personalized medicine. Despite
the fact that the evidence about the role of pharmacogenetics in
children with nephrotic syndrome is limited, we feel that avail-
able data do show a potential role for pharmacogenetics in
clinical practice to maximize drug efficacy, minimize drug tox-
icity, and avoid exposure to ineffective drug courses.
Nowadays, the evidence to implement these genetic markers
in clinical practice is too little and, therefore, clinical implemen-
tation of pharmacogenetics in nephrotic syndrome patients is
not possible yet. Therefore, we feel that further research is high-
ly important to identify specific and sensitive markers for ste-
roid resistance in patients without genetic podocyte mutations
as well as for patients more at risk for steroid-related toxicities.
As nephrotic syndrome is a rare kidney disease in childhood
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and large patient cohorts are needed to ultimately implement
pharmacogenetics in the clinical work-up, we believe that this
research preferably should be conducted in international collab-
orative studies.
Multiple choice questions (answers are
provided following the reference list)
1. Current glucocorticoid dosing guidelines for the treatment
of nephrotic syndrome are
a) Standardized
b) Individualized
c) Based on randomized controlled trials
2. The genomic glucocorticoid action is characterized by
a) A rapid onset of the effect
b) Short duration of the effect
c) A slow onset of the effect
3. Adverse events of prednisone/prednisolone largely result
from
a) Transrepression of pro-inflammatory and immune genes
b) Transactivation of anti-inflammatory genes
4. Due to decreased protein binding of prednisone and pred-
nisolone in patients with nephrotic syndrome and to more
rapid elimination and an increase in volume of distribu-
tion, the steady-state unbound concentration
a) is increased
b) is unchanged
c) is decreased
5. Pharmacogenetics may have an influence on the profile of
the individual patient
a) Pharmacokinetic
b) Pharmacodynamic
c) Pharmacokinetic and pharmacodynamic
d) None of the above
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